Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Approximately 150 million people worldwide are estimated to be chronic carriers of hepatitis C virus (HCV). Estimates indicate a quarter of HCV carriers will develop liver cirrhosis, which entails a risk of severe complications (hepatocellular carcinoma, decompensation, end-stage liver failure, death).1 Viral clearance significantly decreases disease progression and increases survival rates. Two antiviral approaches are currently available: interferon-based and interferon-free. Interferon-free therapies are the future of HCV treatment thanks to the optimal tolerability and safety, high efficacy and because they can be administered regardless of disease stage and impairment of other systems.2 The only approved interferon-free combination is ribavirin with sofosbuvir, which is indicated for genotype 2 or 3 infection, and for genotype 1 infection in case of …
Contributors IG drafted the work, GB revised the work. They both gave the final approval to the version submitted.
Competing interests None.
Provenance and peer review Not commissioned; internally peer reviewed.